Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan.
Cancer Med. 2023 Jan;12(2):1762-1778. doi: 10.1002/cam4.4955. Epub 2022 Jun 30.
The study objectives were to understand how patients view the quality of life in non-metastatic castration-resistant prostate cancer (nmCRPC), including unmet needs and what patients consider most important in treatment outcomes. A gap analysis was conducted on existing patient-reported outcomes (PROs) measures versus what is missing from the patient perspective, to guide future development of PRO-based real-world evidence for nmCRPC in Japan. A conceptual model for nmCRPC Japanese patients' HRQOL was also created.
This non-interventional, qualitative study consisted of a targeted literature review, PRO instrument review, and interviews with 20 nmCRPC patients and five treating physicians. Triangulation of the gap analysis, evidence from the targeted review of the literature, and qualitative interview findings were employed to assess the comprehensiveness of current nmCRPC and HRQOL measures.
Symptoms most reported by patients were frequent urination (70%), nocturia (65%), and general pain (65%). Others reported included lack of strength (30%). HRQOL impacts most reported were anxiety (45%) and worry (50%) about their diagnosis. Additional impacts mentioned were weight changes, loss of sleep, difficulty walking, loss of appetite, and difficulty traveling and seeking toilets in public. The gap analysis revealed 31 symptoms and 33 impacts not covered in existing prostate cancer-specific PRO instruments. Patients mentioned musculoskeletal symptoms such as fractures, leg pain, cramps, numbness, and loss of leg bone strength. Impacts not previously discussed in the literature or in outcome measures were feelings of self-consciousness around diagnosis, stigma around illness, and the impact on mobility including traveling.
Key results reveal pain and urinary symptoms are the most experienced by Japanese nmCRPC patients. The diagnosis and treatment of disease leads to significant impacts in patient lives. Analysis revealed that symptoms and life impacts are missing in the current literature and outcome measures. Testing and debriefing of specific items could further substantiate these dimensions.
本研究旨在了解非转移性去势抵抗性前列腺癌(nmCRPC)患者如何看待生活质量,包括未满足的需求以及患者认为治疗结果中最重要的因素。通过对现有患者报告结局(PRO)测量工具与患者视角缺失内容进行差距分析,为未来在日本开展基于 PRO 的 nmCRPC 真实世界证据提供指导。同时,构建了 nmCRPC 日本患者 HRQOL 的概念模型。
这是一项非干预性、定性研究,包括有针对性的文献回顾、PRO 工具评估以及对 20 名 nmCRPC 患者和 5 名治疗医生的访谈。采用差距分析的三角分析、有针对性的文献综述证据以及定性访谈结果,评估当前 nmCRPC 和 HRQOL 测量工具的全面性。
患者报告的最常见症状为尿频(70%)、夜尿(65%)和全身疼痛(65%)。其他报告的症状包括乏力(30%)。报告的 HRQOL 影响最常见的是焦虑(45%)和对诊断的担忧(50%)。此外,还提到了体重变化、睡眠丧失、行走困难、食欲不振以及在公共场合出行和找厕所困难。差距分析显示,现有前列腺癌特异性 PRO 工具未涵盖 31 种症状和 33 种影响。患者提到了肌肉骨骼症状,如骨折、腿部疼痛、痉挛、麻木和腿部骨骼力量丧失。文献或结局测量中以前未讨论过的影响包括诊断时的自我意识、疾病带来的耻辱感以及对包括出行在内的活动能力的影响。
主要结果表明,疼痛和泌尿系统症状是日本 nmCRPC 患者最常经历的症状。疾病的诊断和治疗对患者的生活产生了重大影响。分析显示,目前的文献和结局测量中存在症状和生活影响的缺失。对特定项目的测试和讨论可以进一步证实这些维度。